Unsurprising reaction, revenue growth slowing and what looks like a failure on the therapy when compared to the currently approved therapy drug
The base was always suspect to me with that nasty selling bar in the middle of it on the last quarterly, topping bases always have large selling bars within them
Ann: Q3 2023 Business Update to Accompany Quarterly Results, page-52
-
- There are more pages in this discussion • 87 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.73 |
Change
0.245(1.40%) |
Mkt cap ! $5.862B | |||
| Open | High | Low | Value | Volume |
| $17.83 | $17.84 | $17.43 | $5.434M | 308.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 294 | $17.72 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.73 | 1270 | 16 |
View Market Depth
| Last trade - 11.50am 09/08/2024 (20 minute delay) ? |
| TLX (ASX) Chart |